Open AccessThe Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation
Author(s) -
Senthilnathan Palaniyandi,
Reena Kumari,
Sabarinath Venniyil Radhakrishnan,
Ethan Strattan,
Natalya Hakim,
Reinhold Munker,
Melissa Kesler,
Gerhard Hildebrandt
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000003383
Subject(s) - medicine , transplantation , immunology , graft versus host disease , tumor necrosis factor alpha , t cell , apoptosis , hematopoietic stem cell transplantation , ileum , biology , immune system , biochemistry
Prolyl hydroxylase inhibitors (PHI) promote stabilization of hypoxia-inducible factor-1 alpha and affect signaling cascades of inflammation and cell death. Their beneficial use in experimental models of ulcerative colitis and lung allograft rejection led us to test the effect of the PHI dimethyl oxalyl glycine (DMOG) in the pathophysiology of graft versus host disease (GVHD).